Monika Szarszewska, Janina Markowska, Marian Grybos, Anna Grybos, Andrzej Marszalek, Anna Malicka-Durczak, Violetta Filas, Michal Michalak, Anna Markowska
{"title":"Irisin - a new biomarker for endometrial cancer?","authors":"Monika Szarszewska, Janina Markowska, Marian Grybos, Anna Grybos, Andrzej Marszalek, Anna Malicka-Durczak, Violetta Filas, Michal Michalak, Anna Markowska","doi":"10.5603/gpl.104455","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Irisin is an adipomyokine that has an inhibitory effect on inflammation and possesses anticancer activity. It inhibits cancer cell proliferation, metastasis, and invasion through various signaling pathways associated with carcinogenesis. It has been described to be associated with a number of malignancies in various locations. It has been recognized that it may be a biomarker and prognostic factor in some malignancies. In addition, studies indicate irisin's possible role in treating malignant lesions.</p><p><strong>Material and methods: </strong>In material including 129 cases of endometrial cancer and normal endometrium in a control group of 18 women with uterine myomas.</p><p><strong>Results: </strong>There were no statistical differences in irisin protein expression. There were also no differences in irisin expression according to clinical stage, type, and histopathological differentiation.</p><p><strong>Conclusions: </strong>Further clinical studies are needed to evaluate irisin activity in endometrial cancer.</p>","PeriodicalId":94021,"journal":{"name":"Ginekologia polska","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ginekologia polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/gpl.104455","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Irisin is an adipomyokine that has an inhibitory effect on inflammation and possesses anticancer activity. It inhibits cancer cell proliferation, metastasis, and invasion through various signaling pathways associated with carcinogenesis. It has been described to be associated with a number of malignancies in various locations. It has been recognized that it may be a biomarker and prognostic factor in some malignancies. In addition, studies indicate irisin's possible role in treating malignant lesions.
Material and methods: In material including 129 cases of endometrial cancer and normal endometrium in a control group of 18 women with uterine myomas.
Results: There were no statistical differences in irisin protein expression. There were also no differences in irisin expression according to clinical stage, type, and histopathological differentiation.
Conclusions: Further clinical studies are needed to evaluate irisin activity in endometrial cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
